These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29110189)

  • 1. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1909-1916. PubMed ID: 29110189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.
    Tang-Liu DD; Acheampong A
    Clin Pharmacokinet; 2005; 44(3):247-61. PubMed ID: 15762768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiinflammatory therapy for dry eye.
    Pflugfelder SC
    Am J Ophthalmol; 2004 Feb; 137(2):337-42. PubMed ID: 14962426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers.
    Labetoulle M; Leonardi A; Pisella PJ; Baudouin C
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1707-1715. PubMed ID: 35766874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
    Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
    Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare.
    Mackenzie CJ; Carslake HB; Robin M; Kent RJ; Malalana F
    Vet Ophthalmol; 2017 Jan; 20(1):79-83. PubMed ID: 26945681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. The Cyclosporine Study Group.
    Tauber J
    Adv Exp Med Biol; 1998; 438():969-72. PubMed ID: 9634996
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease.
    Burade V; Zalawadia R; Patel A; Ogundele A
    Clin Ophthalmol; 2020; 14():2747-2755. PubMed ID: 33061257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
    Marsh P; Pflugfelder SC
    Ophthalmology; 1999 Apr; 106(4):811-6. PubMed ID: 10201607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.
    Stonecipher K; Perry HD; Gross RH; Kerney DL
    Curr Med Res Opin; 2005 Jul; 21(7):1057-63. PubMed ID: 16004673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical ciclosporin in the treatment of ocular surface disorders.
    Tatlipinar S; Akpek EK
    Br J Ophthalmol; 2005 Oct; 89(10):1363-7. PubMed ID: 16170133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.
    Pisella PJ; Labetoulle M; Doan S; Cochener-Lamard B; Amrane M; Ismail D; Creuzot-Garcher C; Baudouin C
    Clin Ophthalmol; 2018; 12():289-299. PubMed ID: 29440872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.